Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


04.02.2019

1 BMC Neurol
1 Exp Brain Res
2 J Neural Transm (Vienna)
1 J Neurol Neurosurg Psychiatry
5 Mov Disord
1 N Engl J Med
1 Neurosci Lett
3 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Neurol

  1. OERTON E, Bender A
    Correction to: Concordance analysis of microarray studies identifies representative gene expression changes in Parkinson's disease: a comparison of 33 human and animal studies.
    BMC Neurol. 2019;19:16.
    PubMed     Text format     Abstract available


    Exp Brain Res

  2. DAVID FJ, Goelz LC, Tangonan RZ, Metman LV, et al
    Bilateral deep brain stimulation of the subthalamic nucleus increases pointing error during memory-guided sequential reaching.
    Exp Brain Res. 2018;236:1053-1065.
    PubMed     Text format     Abstract available


    J Neural Transm (Vienna)

  3. HATTORI N, Takeda A, Takeda S, Nishimura A, et al
    Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson's disease.
    J Neural Transm (Vienna). 2019 Jan 28. pii: 10.1007/s00702-018-1964.
    PubMed     Text format     Abstract available

  4. GRUBER D, Calmbach L, Kuhn AA, Krause P, et al
    Longterm outcome of cognition, affective state, and quality of life following subthalamic deep brain stimulation in Parkinson's disease.
    J Neural Transm (Vienna). 2019 Jan 25. pii: 10.1007/s00702-019-01972.
    PubMed     Text format     Abstract available


    J Neurol Neurosurg Psychiatry

  5. LOW A, Foo H, Yong TT, Tan LCS, et al
    Hippocampal subfield atrophy of CA1 and subicular structures predict progression to dementia in idiopathic Parkinson's disease.
    J Neurol Neurosurg Psychiatry. 2019 Jan 25. pii: jnnp-2018-319592.
    PubMed     Text format     Abstract available


    Mov Disord

  6. SCHEPERJANS F
    The prodromal microbiome.
    Mov Disord. 2018;33:5-7.
    PubMed     Text format    

  7. ALBANESE A
    Classifying tremor: Language matters.
    Mov Disord. 2018;33:3-4.
    PubMed     Text format    

  8. FASANO A, Lang AE, Espay AJ
    What is "essential" about essential tremor? A diagnostic placeholder.
    Mov Disord. 2018;33:58-61.
    PubMed     Text format    

  9. ATKINSON-CLEMENT C, Cavazzini E, Zenon A, Witjas T, et al
    Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson's disease.
    Mov Disord. 2019 Jan 25. doi: 10.1002/mds.27625.
    PubMed     Text format     Abstract available

  10. HUANG X, Sterling NW, Du G, Sun D, et al
    Brain cholesterol metabolism and Parkinson's disease.
    Mov Disord. 2019 Jan 25. doi: 10.1002/mds.27609.
    PubMed     Text format     Abstract available


    N Engl J Med

  11. OLSEN AL, Feany MB
    PARP Inhibitors and Parkinson's Disease.
    N Engl J Med. 2019;380:492-494.
    PubMed     Text format    


    Neurosci Lett

  12. KAWAMURA M, Sato S, Matsumoto G, Fukuda T, et al
    Loss of nuclear REST/NRSF in aged-dopaminergic neurons in Parkinson's disease patients.
    Neurosci Lett. 2019 Jan 23. pii: S0304-3940(19)30054.
    PubMed     Text format     Abstract available


    PLoS One

  13. HARDING Z, Wilkinson T, Stevenson A, Horrocks S, et al
    Identifying Parkinson's disease and parkinsonism cases using routinely collected healthcare data: A systematic review.
    PLoS One. 2019;14:e0198736.
    PubMed     Text format     Abstract available

  14. LANG KC, Hackney ME, Ting LH, McKay JL, et al
    Antagonist muscle activity during reactive balance responses is elevated in Parkinson's disease and in balance impairment.
    PLoS One. 2019;14:e0211137.
    PubMed     Text format     Abstract available

  15. DUCHIN Y, Shamir RR, Patriat R, Kim J, et al
    Patient-specific anatomical model for deep brain stimulation based on 7 Tesla MRI.
    PLoS One. 2018;13:e0201469.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: